Celanese Corporation
NYSE:CEChemicals
-$0.24 today
- Market cap
- $5.29B
- Beta
- 0.74
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$9.98
- Dividend yield
- 0.24%
Volume 1.38M
Average 2.09M
CE Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Celanese CorporationNYSE: CE
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures declines year over year
Q2 FY2026 capital expenditures of $62M (cash outflow) fell 33.3% year over year, behind the -28.9% change in trailing-twelve-month capital expenditures. Sequentially, it fell 6.1% from the prior quarter. Over 3 fiscal years it compounded at -14.2% a year.
Context
- Capital expenditures amounted to 3.6% of revenue in FY2025, down 0.6 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -33.3% toward the trailing-twelve-month pace of -28.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (343M) USD
- Year-over-year change
- +21.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (343M) | +21.1% |
| FY2024 | 2024-12-31 | (435M) | +23.4% |
| FY2023 | 2023-12-31 | (568M) | -4.6% |
| FY2022 | 2022-12-31 | (543M) | -16.3% |
| FY2021 | 2021-12-31 | (467M) | — |
Capital Expenditures vs competitors
How CE compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.9% is the 8th highest of 11, against a peer median of +4.1%.
- Capital expenditures amounts to 2.8% of revenue for CE, versus a peer median of 5.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2026 | ZAR 20.55B ZAR | -19.1% | -12.6% | 7.7% | |
| LTM Jun 2026 | $276M USD | -28.9% | -14.2% | 2.8% | |
| LTM Jun 2026 | $246.4M USD | +245.5% | +19.4% | 12.7% | |
| LTM Jun 2026 | $216M USD | -28.5% | +9.1% | 5.9% | |
| LTM Aug 2026 | $189.33M USD | +56.4% | +3.1% | 5.3% | |
| LTM Mar 2026 | $154.44M USD | -81.6% | +90.6% | 11.9% | |
| LTM Jun 2026 | $118.89M USD | +59.8% | +4.1% | 7.0% | |
| LTM Jun 2026 | $71M USD | -30.4% | -4.6% | 3.9% | |
| LTM Sep 2026 | $56.25M USD | +27.4% | +6.4% | 4.9% | |
| LTM Sep 2026 | $16.21M USD | -59.5% | -4.7% | 1.5% | |
| LTM Mar 2026 | $35K USD | +114.3% | -40.6% | — | |
| Peer median (excluding CE) | — | +4.1% | +3.6% | 5.9% | |
Competitors are the stored peer set for CE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.89B | 1.9B | 1.96B | (1.51B) | (1.14B) |
| Depreciation & Amortization | 378M | 478M | 711M | 823M | 786M |
| Deferred Income Tax | 13M | (835M) | (967M) | 216M | (278M) |
| Stock-Based Compensation | 95M | 60M | 40M | 32M | 0 |
| Change in Working Capital | (488M) | 280M | 516M | (204M) | 235M |
| Accounts Receivables | (396M) | 218M | 105M | 92M | 213M |
| Inventory | (367M) | (253M) | 398M | 11M | 154M |
| Accounts Payables | 353M | (84M) | 20M | (234M) | 26M |
| Other Working Capital | (78M) | 399M | (7M) | (73M) | (158M) |
| Other Non-Cash Items | (131M) | (66M) | (365M) | 1.61B | 1.55B |
| Operating Cash Flow | 1.76B | 1.82B | 1.9B | 966M | 1.15B |
| Capital Expenditures | (467M) | (543M) | (568M) | (435M) | (343M) |
| Acquisitions (Net) | (1.12B) | (10.54B) | 532M | 0 | 21M |
| Purchases of Investments | 467M | 0 | 0 | 0 | 0 |
| Sales of Investments | 516M | 0 | 0 | 17M | 0 |
| Other Investing Activities | (520M) | (57M) | (98M) | (52M) | (27M) |
| Investing Cash Flow | (1.12B) | (11.14B) | (134M) | (470M) | (349M) |
| Debt Repayment | 404M | 10.78B | (1.09B) | (948M) | (323M) |
| Common Stock Issued | 0 | 0 | 0 | 1M | 0 |
| Common Stock Repurchased | (1B) | (17M) | 0 | 0 | 0 |
| Dividends Paid | (304M) | (297M) | (305M) | (307M) | (13M) |
| Other Financing Activities | (142M) | (175M) | (63M) | (59M) | (177M) |
| Financing Cash Flow | (1.04B) | 10.29B | (1.46B) | (1.31B) | (513M) |
| Effect of Forex Changes | (15M) | 4M | (12M) | (26M) | 17M |
| Net Change in Cash | (419M) | 972M | 297M | (843M) | 301M |
| Free Cash Flow | 1.29B | 1.28B | 1.33B | 531M | 803M |
Celanese Corporation
NYSE:CE
Intrinsic Alpha fair value
Locked
Current Price
$48.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.